FOMX - Foamix Pharmaceuticals Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.6900
+0.0300 (+1.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.6600
Open2.6900
Bid2.6700 x 900
Ask2.7300 x 1200
Day's Range2.6200 - 2.7400
52 Week Range2.3000 - 7.6000
Volume309,589
Avg. Volume278,885
Market Cap146.405M
Beta (3Y Monthly)2.28
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barclays Has New Plays for Healthcare Fans
    SmarterAnalyst3 days ago

    Barclays Has New Plays for Healthcare Fans

    Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays'  has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * Village Farms (VFF) Has a Lot Going for It * Hexo Has Difficult Days Ahead, Analyst Says * Square (SQ) Growth Slowing, But Evercore Remains Bullish on the Stock * This Analyst Sticks with His Buy Rating on Aphria (APHA) Stock, But Trims Price Target

  • Thomson Reuters StreetEvents29 days ago

    Edited Transcript of FOMX earnings conference call or presentation 8-May-19 12:30pm GMT

    Q1 2019 Foamix Pharmaceuticals Ltd Earnings Call

  • Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now
    SmarterAnalystlast month

    Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now

    Get ready, bargain shoppers. Foamix (FOMX) has plummeted 27% since the beginning of the year and it looks like the stock received more lashes than it deserved -- at least, according to Wall Street analysts.2019 is poised to be a transformative year for Foamix. The company's acne treatment FMX101 is currently pending regulatory review in the U.S, and a PDUFA date of October 20, 2019 has been set. Furthermore, Foamix plans to submit a New Drug Application (NDA) for FMX103 during mid-2019, following positive long-term safety data in papulopustular rosacea patients. Now, let's take a closer look at what analysts are expecting ahead of October's FDA decision.FMX101's Approval Chances and ForecastsCredit Suisse analyst Vamil Divan sees a high likelihood of regulatory approval for FMX101, applying a 90% probability of success (POS). The analyst rates FOMX stock an Outperform with a $9.00 price target, which implies nearly 250% upside from current levels. With an FDA approval in hand (100% POS), Divan says his price target will be boosted to $11.00. According to the analyst, "an increase in the sample size (1,507 patients in this trial vs. ~500 each in the two prior trials) and improved site selection and training helped drive statistically significant [clinical] results," which put the company on track to win FDA approval.Similarly, H.C Wainright analyst Ram Selvaraju estimates the probability of regulatory approval at 85%, and assigns a $12.00 price target for the stock. If the price target is reached within 12 months, that would provide a 12-month return of nearly 360%. Selvaraju opined, "We believe that the current valuation situation presents an attractive entry point for value-focused investors, given the fact that Foamix currently trades about 2x book value [...] Our risk-adjusted net present value (rNPV) of FMX101 is $400M, which factors in an 85% probability of regulatory approval [...] We have employed a sum-of-the-parts valuation approach that yields a total projected firm value of $696M, which translates into a price objective of $12.00 assuming ~59M fully-diluted shares outstanding as of end-2019."Commercial Opportunity Selvaraju believes investors seem to be discounting both FMX101 and FMX103 from a commercial standpoint, but "this is unwarranted." Why? "These agents are based on well-known, validated and effective compounds in their respective target indications and have generated statistically significant efficacy data in large, robustlypowered pivotal studies. We also draw investors' attention to the large size and underserved nature of the target markets—namely, acne and rosacea—and the willingness of patients and physicians alike to try new formulations when they are introduced. Furthermore, we point to the user-friendly and well-tolerated nature of the Foamix formulations, which utilize the company's proprietary foam-based delivery technology to enhance efficacy while minimizing off-target systemic side effects," Selvaraju answers.Cowen analyst Ken Cacciatore has recently spoken with 3 dermatology KOLs; they all agreed that "the clinical data were as good or better than they would have expected," and, according to the analyst, one has indicated that "it looked "more impressive" than Aczone (which peaked at over $200MM+ before genericization)." Cacciatore believes that given the wide use of oral minocycline, clinicians are eager to have this option with potential similar efficacy yet without the the systemic side effects, and therefore, the marketing of FMX-101 should be a very easy story to tell. The analyst says "FMX-101 should be able to easily surpass the peak prescription levels of Aczone (via our consultants' feedback)," and "this would place FMX-101 to achieve at least $250MM in revenue." Furthermore, the analyst believes FMX-101 could ultimately reach his target of $350MM given what he believes will be "improved efficacy/outcomes." Cacciatore argues that "even undifferentiated dermatology assets are selling at 3x peak revenue. Using just FMX-101 alone – and the low-end ($250MM) of what we believe will be the ultimate product size – would yield a value of $750MM, or $13-15 per share."Bottom lineFoamix has seen its shares struggle mightily this year, but analysts continue to believe that this beaten-down biotech stock is a sure-fire winner. Analysts are confident that lead asset, FMX101, has substantial potential in treating acne, with an upcoming October 20, 2019 PDUFA date as a key potential positive catalyst for FOMX shares.This latest pullback has arguably skewed the risk-to-reward ratio for the better -- perhaps making FOMX an attractive buy for risk-tolerant investors. More recent articles from Smarter Analyst: * Village Farms (VFF) Has a Lot Going for It * Hexo Has Difficult Days Ahead, Analyst Says * Square (SQ) Growth Slowing, But Evercore Remains Bullish on the Stock * This Analyst Sticks with His Buy Rating on Aphria (APHA) Stock, But Trims Price Target

  • Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX): The Best Of Both Worlds
    Simply Wall St.last month

    Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX): The Best Of Both Worlds

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Foamix Pharmaceuticals (FOMX) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Foamix Pharmaceuticals (FOMX) Q1 2019 Earnings Call Transcript

    FOMX earnings call for the period ending March 31, 2019.

  • Foamix (FOMX) Reports Q1 Loss, Misses Revenue Estimates
    Zackslast month

    Foamix (FOMX) Reports Q1 Loss, Misses Revenue Estimates

    Foamix (FOMX) delivered earnings and revenue surprises of -16.67% and -67.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Foamix: 1Q Earnings Snapshot

    The Rehovot, Israel-based company said it had a loss of 28 cents per share. The acne treatment developer posted revenue of $308,000 in the period. In the final minutes of trading on Tuesday, the company's ...

  • Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know
    Zacks2 months ago

    Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know

    Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • This Small-Cap Biotech Stock Could Triple in 2019
    GuruFocus.com2 months ago

    This Small-Cap Biotech Stock Could Triple in 2019

    Investing in biotech stocks can provide true binary opportunities. If the drug succeeds, small-cap biotech stocks easily become multi-baggers. Warning! GuruFocus has detected 2 Warning Signs with FOMX.

  • What Kind Of Share Price Volatility Should You Expect For Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)?
    Simply Wall St.2 months ago

    What Kind Of Share Price Volatility Should You Expect For Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Anyone researching Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) might want to consider the historical volatility of the share pr...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of FOMX earnings conference call or presentation 1-Mar-19 1:30pm GMT

    Q4 2018 Foamix Pharmaceuticals Ltd Earnings Call

  • How Many Insiders Bought Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Shares?
    Simply Wall St.4 months ago

    How Many Insiders Bought Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...

  • Are Foamix Pharmaceuticals Ltd.’s (NASDAQ:FOMX) Interest Costs Too High?
    Simply Wall St.5 months ago

    Are Foamix Pharmaceuticals Ltd.’s (NASDAQ:FOMX) Interest Costs Too High?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...

  • Is Foamix Pharmaceuticals Ltd (FOMX) A Good Stock To Buy?
    Insider Monkey6 months ago

    Is Foamix Pharmaceuticals Ltd (FOMX) A Good Stock To Buy?

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]

  • Simply Wall St.6 months ago

    Could Foamix Pharmaceuticals Ltd.’s (NASDAQ:FOMX) Investor Composition Influence The Stock Price?

    A look at the shareholders of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to Read More...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of FOMX earnings conference call or presentation 9-May-18 12:30pm GMT

    Q1 2018 Foamix Pharmaceuticals Ltd Earnings Call

  • Benzinga7 months ago

    The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 19) Merck & Co., Inc. (NYSE: MRK ) Down In The Dumps (Biotech ...

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of FOMX earnings conference call or presentation 8-Nov-18 1:30pm GMT

    Q3 2018 Foamix Pharmaceuticals Ltd Earnings Call

  • Foamix (FOMX) Reports Q3 Loss, Lags Revenue Estimates
    Zacks7 months ago

    Foamix (FOMX) Reports Q3 Loss, Lags Revenue Estimates

    Foamix (FOMX) delivered earnings and revenue surprises of -22.58% and -21.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Reuters7 months ago

    Foamix's treatment for common skin condition meets late-stage trial goals

    Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-stage clinical trials. The treatment, code-named FMX103 and made up of an antibiotic commonly used to treat infections, significantly reduced inflammatory lesions, compared to a foam without the antibiotic, minocycline. The two late-stage studies enrolled over a thousand patients suffering from papulopustular rosacea, which causes lesions to break out on the face, and the mostly commonly reported side effects were upper respiratory tract infections, the company said.

  • Implied Volatility Surging for Foamix (FOMX) Stock Options
    Zacks8 months ago

    Implied Volatility Surging for Foamix (FOMX) Stock Options

    Investors need to pay close attention to Foamix (FOMX) stock based on the movements in the options market lately.

  • Simply Wall St.8 months ago

    Does Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Have A High Beta?

    If you own shares in Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • Foamix's Acne Candidate Succeeds in Study, Shares Rally
    Zacks9 months ago

    Foamix's Acne Candidate Succeeds in Study, Shares Rally

    Foamix's (FOMX) acne candidate, FMX101, meets co-primary endpoints in the third phase III study, FX2017-22.